Design Therapeutics, Inc. DSGN
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +8.21%
- 1 year
- +51.49%
- Open
- 10.70
- Prev close
- 10.68
- Mkt cap
- 635.20M
- Vol
- 288.50K
- Avg vol
- 582.13K
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.13
- High
- 10.74
- Forward P/E
- -5.13
- Beta
- 1.83
- Short ratio
- 19.61
- Inst. own
- 56.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 5.88
- 200-d avg
- 4.63
- 1y target
- 7.00
Key statistics
- Market cap
- 351.62M
- Enterprise value
- 102.33M
- Trailing P/E
- 0.00
- Forward P/E
- -5.13
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.39
- EPS (TTM)
- -0.85
- Beta
- 1.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -30.07M
- Total cash
- 254.07M
- Total debt
- 2.52M
- Return on equity
- -17.78%
- Shares outstanding
- 56.62M
- Short % of float
- 10.61%
- 50-day average
- 5.88
- 200-day average
- 4.63
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 7.00
- Target (high)
- 12.00
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 5, 2024
Expected Aug 5, 2024. Consensus EPS estimate -0.26667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.26 | -0.23 | +0.03 | +11.54% |
| Aug 5, 2024 | Jun 1, 2024 | -0.25 | -0.21 | +0.04 | +16.00% |
| Aug 5, 2024 | Jun 1, 2024 | -0.25 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.28 | -0.20 | +0.08 | +28.57% |
| May 8, 2024 | Mar 1, 2024 | -0.28 | — | — | — |
| Mar 19, 2024 | Dec 1, 2023 | -0.32 | -0.21 | +0.11 | +34.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| May 7, 2024 | Piper Sandler | up | Neutral | Overweight |
| Mar 20, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Mar 20, 2024 | Wedbush | reit | Neutral | Neutral |
| Nov 14, 2023 | RBC Capital | main | Sector Perform | Sector Perform |
| Aug 15, 2023 | Wedbush | down | Outperform | Neutral |
About Design Therapeutics, Inc.
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- designtx.com
News
- Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26
- Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
- Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1
- TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
- Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
- Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May
- Nasdaq Down 200 Points; Brady Earnings Top Views
- Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability Score
- Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock
Your note
Sign in to keep a note on DSGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERGER HEATHER A | Director | Purchase | Mar 24, 2024 | 1,300 |
| LAPPE RODNEY W | Director | Purchase | Sep 28, 2023 | 133,024 |
| PRASAD DEEPA | Director | Sale | Dec 17, 2024 | 20,000 |
| SCHMID JOHN P | Director | Purchase | Mar 24, 2024 | 0 |
| WILLIAM ARSANI H. | Director | Sale | Aug 8, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SR One Capital Management, LP | 11.53% | 6,526,476 | 40.53M | Sep 29, 2024 |
| Logos Global Management LP | 7.45% | 4,217,627 | 26.19M | Sep 29, 2024 |
| Blackrock Inc. | 4.17% | 2,358,797 | 14.65M | Sep 29, 2024 |
| Frazier Life Sciences Management, L.P. | 3.34% | 1,892,547 | 11.75M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 3.08% | 1,743,725 | 10.83M | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 2.83% | 1,600,740 | 9.94M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.46% | 829,100 | 5.15M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.43% | 809,268 | 5.03M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.41% | 800,901 | 4.97M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.71% | 399,505 | 2.48M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.57% | 320,414 | 1.99M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.52% | 292,403 | 1.82M | Oct 30, 2024 |